HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Citius Pharma (NASDAQ:CTXR) and maintained a $4 price target.
February 14, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharma receives a reiterated Buy rating and a maintained $4 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong analyst confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term uptick in CTXR's stock price, given the direct recommendation and specific price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100